---
title: Export growth and international competitiveness
videoId: WkylI-78U6c
---

From: [[asianometry]] <br/> 

India's economy is predominantly service-based, with pharmaceuticals being a significant exception where manufacturing has intensified <a class="yt-timestamp" data-t="00:00:03">[00:00:03]</a>. As of 2020, India possesses the third-largest pharmaceutical industry by volume and the eleventh largest by value, experiencing rapid growth <a class="yt-timestamp" data-t="00:00:12">[00:00:12]</a>. The country is the world's leading provider of generic drugs, supplying 40% of generics to the United States <a class="yt-timestamp" data-t="00:00:22">[00:00:22]</a>. In 2020, India's pharmaceutical exports exceeded imports by $16 billion, meeting strict international standards <a class="yt-timestamp" data-t="00:00:30">[00:00:30]</a>.

## Historical Context and Early Challenges

Following India's independence in 1947, millions lacked access to essential drugs <a class="yt-timestamp" data-t="00:01:22">[00:01:22]</a>. The domestic drug industry was heavily controlled by foreign multinationals, primarily from the UK, France, and Germany, which held a 90% market share <a class="yt-timestamp" data-t="00:01:30">[00:01:30]</a>. Indian companies largely focused on marketing and distributing foreign drugs, leading to almost complete reliance on imports <a class="yt-timestamp" data-t="00:01:42">[00:01:42]</a>. Domestic drug prices were among the highest globally, with 99% of drugs protected by patents, limiting access to only the wealthy <a class="yt-timestamp" data-t="00:01:52">[00:01:52]</a>.

To address this reliance, the Indian government established public sector pharmaceutical firms, including Hindustan Antibiotics Limited in 1954 and Indian Drugs and Pharmaceuticals Limited in cooperation with the Soviets a few years later <a class="yt-timestamp" data-t="00:02:14">[00:02:14]</a>.

### The Patent Act of 1970: A Turning Point

A pivotal moment occurred when an Indian company, Cipla, manufactured a generic version of propranolol, a high blood pressure medication developed by ICI Pharmaceuticals that was too expensive for India <a class="yt-timestamp" data-t="00:02:31">[00:02:31]</a>. Cipla's R&D head, Yusuf Hamied, justified their actions to Prime Minister Indira Gandhi, who then urged parliament to modify drug patent laws <a class="yt-timestamp" data-t="00:02:57">[00:02:57]</a>.

This led to the **Patent Act of 1970**, which revitalized the Indian pharmaceutical industry <a class="yt-timestamp" data-t="00:03:12">[00:03:12]</a>. Its two main goals were to ensure low-cost access to drugs and to foster an indigenous Indian pharmaceutical industry through import substitution <a class="yt-timestamp" data-t="00:03:21">[00:03:21]</a>.

The act replaced the previous product-based patent system (rooted in British IP law from 1872) with a new system that protected the *process* rather than the *product* <a class="yt-timestamp" data-t="00:03:36">[00:03:36]</a>. It also set shorter time limits for process patents (five to seven years compared to 15 years) <a class="yt-timestamp" data-t="00:04:07">[00:04:07]</a>. Furthermore, the Indian patent office could force patent holders to license patents at a reasonable rate if they were not being used in a socially beneficial way <a class="yt-timestamp" data-t="00:04:17">[00:04:17]</a>. This opened up significant opportunities for the Indian pharmaceutical industry to reverse-engineer popular imported drugs <a class="yt-timestamp" data-t="00:04:31">[00:04:31]</a>.

### Competency Through Reverse Engineering

In the early stages, Indian companies primarily reverse-engineered existing drugs by studying their production steps and making slight modifications <a class="yt-timestamp" data-t="00:07:48">[00:07:48]</a>. This seemingly derivative approach helped domestic companies gain substantial competency in pharmaceuticals <a class="yt-timestamp" data-t="00:08:44">[00:08:44]</a>. By the late 1980s, Indian pharmaceutical companies could manufacture almost any new molecule without needing the original innovator's recipes <a class="yt-timestamp" data-t="00:08:52">[00:08:52]</a>.

The time lag between the introduction of original innovations and Indian generics steadily narrowed:
*   Ibuprofen (world market 1967): India's first generic in 1973 (6 years) <a class="yt-timestamp" data-t="00:09:15">[00:09:15]</a>.
*   Ciprofloxacin (world market 1986): India's generic in 1989 (3 years) <a class="yt-timestamp" data-t="00:09:26">[00:09:26]</a>.

By 2006, Indian companies supplied 95% of the country's drugs, marking the success of the import substitution policy <a class="yt-timestamp" data-t="00:09:56">[00:09:56]</a>.

## Challenges and the Shift to Global Markets

While the 1970 patent act fostered growth, it also had drawbacks:
*   **Low Value, High Volume**: The industry created was high in volume but low in value, with low barriers to entry and little capital needed to start a firm <a class="yt-timestamp" data-t="00:10:11">[00:10:11]</a>.
*   **Fragmentation**: By 1990, there were approximately 16,000 pharmaceutical companies, leading to extreme fragmentation with up to 100 brands for a single molecule <a class="yt-timestamp" data-t="00:10:22">[00:10:22]</a>.
*   **Low R&D Investment**: Without incentives or protections, the domestic industry did not invest meaningfully in R&D or produce many new drugs <a class="yt-timestamp" data-t="00:10:53">[00:10:53]</a>.

By the 1990s, around 40% of Indian drug production was for export, though these were mostly low-value products, limiting access to more valuable markets <a class="yt-timestamp" data-t="00:11:04">[00:11:04]</a>.

### TRIPS Agreement and International Integration

In 1992, India signed the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), a major milestone that pushed the industry towards indigenous innovation <a class="yt-timestamp" data-t="00:11:21">[00:11:21]</a>. TRIPS required India to amend its patent policies to align with international trade standards, including recognizing product patents and granting exclusive marketing rights to new products <a class="yt-timestamp" data-t="00:11:37">[00:11:37]</a>.

The agreement was controversial, but India was given until 2005 to prepare its drug industry <a class="yt-timestamp" data-t="00:11:53">[00:11:53]</a>. From 1992 to 2005, the industry underwent a monumental shift from its decades-old successful model to a new, more profitable one <a class="yt-timestamp" data-t="00:12:35">[00:12:35]</a>.

Indian firms adapted in several ways:
*   **Increased R&D**: A few firms, like Ranbaxy, Dr. Reddy's Laboratories (DRL), and Wockhardt, invested in R&D to climb the value chain and enter drug discovery <a class="yt-timestamp" data-t="00:12:52">[00:12:52]</a>. New drug compounds discovered increased from 13 (1956-1987) to 7 (1991-2005), and annual R&D spend accelerated from 4.9% (pre-1992) to 6.6% (post-1992) <a class="yt-timestamp" data-t="00:13:06">[00:13:06]</a>. Indian institutions saw a significant rise in pharmaceutical drug patents <a class="yt-timestamp" data-t="00:13:37">[00:13:37]</a>. The government encouraged R&D through various schemes and a pharmaceutical R&D support fund <a class="yt-timestamp" data-t="00:13:55">[00:13:55]</a>.
*   **Diversification**: Many firms, acknowledging the high cost and time commitment of drug discovery, diversified into drug-adjacent fields like drug delivery or strengthened other parts of the value chain like marketing and production <a class="yt-timestamp" data-t="00:14:46">[00:14:46]</a>.
*   **Strategic Collaborations**: Companies like Zydus Cadila and Biocon engaged in [[collaboration_with_global_suppliers | strategic collaboration]] deals with multinational corporations globally, gaining competency and knowledge <a class="yt-timestamp" data-t="00:15:07">[00:15:07]</a>.
*   **Mergers & Acquisitions**: Others pursued mergers and acquisitions to scale up and match the size of Western multinationals <a class="yt-timestamp" data-t="00:15:43">[00:15:43]</a>.

## Export-Driven Growth and [[global_competitiveness_in_regional_jet_manufacturing | International Competitiveness]]

TRIPS implementation significantly pushed India's pharmaceutical companies towards the export market <a class="yt-timestamp" data-t="00:16:01">[00:16:01]</a>. Once the industry met its IP regulation responsibilities, the global market opened up <a class="yt-timestamp" data-t="00:16:09">[00:16:09]</a>.

Today, India's generics industry is highly [[global_competitiveness_in_regional_jet_manufacturing | internationally competitive]], bolstered by lower costs and expertise gained from intense domestic competition <a class="yt-timestamp" data-t="00:16:15">[00:16:15]</a>. A favorable generic drug regulatory environment, including the U.S. Hatch-Waxman Act of 1984 which eased generic drug approval, also contributed <a class="yt-timestamp" data-t="00:16:27">[00:16:27]</a>.

Export intensity grew significantly:
*   **Dr. Reddy's Laboratories**: Export ratio increased from 53% (2000-2005) to 74% (2012-2017) <a class="yt-timestamp" data-t="00:16:39">[00:16:39]</a>.
*   **Marksans Pharma**: Export ratio rose from 21.2% (2000-2005) to 97.5% (2012-2017) <a class="yt-timestamp" data-t="00:16:53">[00:16:53]</a>.
*   **Industry Average**: The whole industry's export intensity grew at an average rate of about 13% after the 2005 TRIPS implementation <a class="yt-timestamp" data-t="00:17:04">[00:17:04]</a>. The industry has nearly octupled in size since, with sales to North America, Africa, and Asia <a class="yt-timestamp" data-t="00:17:13">[00:17:13]</a>.

## Concerns and Future Outlook

A key concern for India's pharmaceutical industry is its increasing dependence on China for Active Pharmaceutical Ingredients (APIs), the essential raw materials for finished drugs <a class="yt-timestamp" data-t="00:17:21">[00:17:21]</a>. India relies on China for 70% of its API imports, particularly antibiotics, which have tripled since 2005 <a class="yt-timestamp" data-t="00:17:40">[00:17:40]</a>. India lost this domestic market in the 1990s due to cheaper Chinese products (40% cheaper at the time, still 20% cheaper today) <a class="yt-timestamp" data-t="00:17:54">[00:17:54]</a>.

This weakness became pronounced in 2020 during China's lockdowns, when Chinese vendors restricted API exports <a class="yt-timestamp" data-t="00:18:11">[00:18:11]</a>. Given ongoing geopolitical tensions, the Indian industry and government should work together on new import substitution policies for these critical ingredients <a class="yt-timestamp" data-t="00:18:25">[00:18:25]</a>.

Ironically, as India moved away from process-based patents, other countries began adopting similar approaches after observing India's success in lowering drug costs and breaking multinational control <a class="yt-timestamp" data-t="00:18:41">[00:18:41]</a>. India's pharmaceutical success is a prime example of market-driven reform stemming from changes in the environment, demonstrating an adaptive approach rather than sticking to an ideology that wasn't working <a class="yt-timestamp" data-t="00:19:11">[00:19:11]</a>. Despite remaining concerns, India's pharmaceutical industry is poised to play a crucial role in addressing global health issues <a class="yt-timestamp" data-t="00:19:31">[00:19:31]</a>.